Skip to main content
CRBP $2.06 -15.40%
CRBP logo
CRBP · Corbus Pharmaceuticals Holdings, Inc.
Track CRBP — free
$2.06 -0.38 (-15.40%) At close · Nov 20 Q4 2020 earnings call transcript
Market Cap
$42.45M
Shares
20.61M
Volume · Nov 20 1.38M Avg daily vol (3M) 1.1M
All webcasts

Earnings call · FY2026 Q3

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q3 2026 Earnings Call

Concluded Nov 15, 2026
Nov 15, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$1.81
Net income -$37.75M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 10, 2026
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $37.8 million for Q3 2026 and held $115.3 million in cash, cash equivalents, and investments, expected to fund operations into 2028. CRB-913 achieved 5% mean weight loss after 12 weeks.
10-Q report · filed Nov 10, 2026
Corbus Pharmaceuticals Holdings reported that CRB-913’s 60 mg dose achieved mean 5% weight loss at 12 weeks. Nine-month 2026 net loss widened to $95.8 million from $58.0 million, with $115.3 million in cash at September 30, 2026.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document